| Literature DB >> 30038625 |
Margarita Álvarez-Rodríguez1, Patricia Pereiro1, Felipe E Reyes-López2, Lluis Tort2, Antonio Figueras1, Beatriz Novoa1.
Abstract
In recent years, the innate immune response has gained importance since evidence indicates that after an adequate priming protocol, it is possible to obtain some prolonged and enhanced immune responses. Nevertheless, several factors, such as the timing and method of administration of the immunostimulants, must be carefully considered. An inappropriate protocol can transform the treatments into a double-edged sword for the teleost immune system, resulting in a stressful and immunosuppressive state. In this work, we analyzed the long-term effects of different stimuli (β-glucans, lipopolysaccharide, and polyinosinic:polycytidylic acid) on the transcriptome modulation induced by Spring Viremia Carp Virus (SVCV) in adult zebrafish (Danio rerio) and on the mortality caused by this infection. At 35 days post-immunostimulation, the transcriptome was found to be highly altered compared to that of the control fish, and these stimuli also conditioned the response to SVCV challenge, especially in the case of β-glucans. No protection against SVCV was found with any of the stimuli, and non-significant higher mortalities were even observed, especially with β-glucans. However, in the short term (pre-stimulation with β-glucan and infection after 7 days), slight protection was observed after infection. The transcriptome response in the zebrafish kidney at 35 days posttreatment with β-glucans revealed a significant response associated with stress and immunosuppression. The identification of genes that were differentially expressed before and after the infection seemed to indicate a high energy cost of the immunostimulation that was prolonged over time and could explain the lack of protection against SVCV. Differential responses to stress and alterations in lipid metabolism, the tryptophan-kynurenine pathway, and interferon-gamma signaling seem to be some of the mechanisms involved in this response, which represents the end of trained immunity and the beginning of a stressful state characterized by immunosuppression.Entities:
Keywords: IFN-γ; TDO; immunostimulants; kynurenine; stress; tolerance; zebrafish; β-glucans
Year: 2018 PMID: 30038625 PMCID: PMC6047052 DOI: 10.3389/fimmu.2018.01575
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Analysis of gene modulation in the zebrafish kidney at 35 days poststimulation with the three pathogen-associated molecular patterns (PAMPs) compared to individuals inoculated with phosphate-buffered saline. (A) Stacked column chart reflecting the distribution of the DEGs. Statistically significant differentially expressed genes are subdivided according to intensity (fold change) and sense (up- and downregulation). (B) Venn diagram showing the number of shared and exclusive modulated genes in the three treated groups. Even after 35 days, the response was found to be very exclusive depending on the PAMP.
Figure 2Analysis of gene modulation in the zebrafish kidney at 24 h postinfection with Spring Viremia Carp Virus (SVCV) in individuals that were previously stimulated with pathogen-associated molecular patterns (PAMPs). (A) Stacked column chart reflecting the distribution of the DEGs compared to individuals inoculated with phosphate-buffered saline (PBS). Statistically significant differentially expressed genes are subdivided according to intensity (fold change) and sense (up- and downregulation). (B) Venn diagram showing the number of shared and exclusive modulated genes after SVCV challenge in the three treated groups compared to PBS-SVCV fish. As observed in the absence of infection, the response was very exclusive depending on the PAMP.
Figure 3Similarity analysis of the transcriptome response at 35 days post-immunostimulation in the presence or absence of Spring Viremia Carp Virus (SVCV) infection. (A) Dendrogram and heatmap representing the overall microarray results. The samples were divided into two clusters, one containing the pathogen-associated molecular patterns (PAMP)-stimulated groups and the individuals infected in the absence of pre-stimulation, and the other including the groups that were pre-stimulated with PAMPs and then infected with SVCV. In both clusters, the β-glucans formed a separate branch, indicating that this stimulus induced the most differential response. (B) Functional classification of DEGs in the zebrafish kidney between the different treatments and the phosphate-buffered saline-treated group according to Slim Biological Process Gene Ontology Terms. The level 1 category “Immune System Process” was selected, and within that category, the level 2 category “Immune Response.” After SVCV challenge, the gene categorization was conditioned by previous stimulation with a PAMP.
Figure 4Effect of pathogen-associated molecular patterns (PAMPs) on the survival of adult zebrafish after a Spring Viremia Carp Virus (SVCV) challenge. (A) Kaplan–Meier survival curves after an SVCV i.p. challenge. Fish were stimulated with PAMPs or inoculated with phosphate-buffered saline (PBS), and 35 days after a single-dose administration, they were i.p. challenged with SVCV. No significant differences were observed among the different groups, although the PAMP-treated zebrafish showed a lower survival rate. (B) Kaplan–Meier survival curves after SVCV i.p. challenge. Fish were previously inoculated with β-glucans or PBS and i.p. challenged with SVCV 7 days after a single-dose administration. A slight but significant increase in the survival rate was observed in fish that were previously treated with β-glucans. Significant differences are represented by asterisks (*p < 0.05).
Top 25 most up- and downregulated genes in β-glucan-treated zebrafish compared to unstimulated fish in the absence (A) or presence (B) of Spring Viremia Carp Virus (SVCV) infection.
| F-box protein 36a | 4.1 |
| G protein-coupled receptor 35, tandem duplicate 1 | 4.0 |
| Crystallin, gamma M2c | 3.8 |
| Golgin subfamily A member 6-like protein 22 | 3.3 |
| Troponin I type 1b | 3.2 |
| Fibronectin type III domain-containing protein 4-like | 3.1 |
| Tumor necrosis factor receptor superfamily, member 9b | 3.0 |
| Phospholipase C-like 1 | 3.0 |
| Adhesion G protein-coupled receptor F8 | 2.8 |
| Relaxin/insulin-like family peptide receptor 3.3b | 2.8 |
| ERBB receptor feedback inhibitor 1 | 2.7 |
| Inner membrane protein, mitochondrial (mitofilin) | 2.6 |
| Heterogeneous nuclear ribonucleoprotein A3 | 2.4 |
| PDZ domain containing 3b | 2.4 |
| Testis-enhanced gene transcript (BAX inhibitor 1) | 2.4 |
| Cerebellin 9 | 2.4 |
| Sema domain, immunoglobulin domain (Ig), short basic domain, secreted (semaphorin) 3bl | 2.3 |
| Protein phosphatase 6, regulatory subunit 2 | 2.3 |
| Cilia and flagella associated protein 126 | 2.2 |
| Actin, alpha 1a, skeletal muscle | 2.2 |
| FAD-dependent oxidoreductase domain containing 2 | 2.2 |
| Angiopoietin-like 2b | 2.1 |
| Transgelin | 2.1 |
| DnaJ (Hsp40) homolog, subfamily C, member 28 | 1.8 |
| THAP domain containing 5 | 1.7 |
| Cytochrome P450, family 8, subfamily B, polypeptide 3 | 8.7 |
| Angiotensinogen | 6.5 |
| Small integral membrane protein 1 | 6.1 |
| Growth arrest and DNA-damage-inducible, beta a | 4.5 |
| Ephrin-A3b | 4.4 |
| Zinc finger protein 1065 | 4.3 |
| Chemokine (C-X-C motif) receptor 5 | 4.2 |
| Subcommissural organ spondin | 4.0 |
| Dachshund b | 3.9 |
| Tubulin tyrosine ligase-like family, member 12 | 3.8 |
| ATPase, class I, type 8B, member 5a | 3.4 |
| Forkhead box F2b | 3.4 |
| Potassium voltage-gated channel, Shaw-related subfamily, member 1b | 3.3 |
| Proteoglycan 4b | 3.3 |
| Zinc finger protein 1059 | 3.2 |
| Tumor necrosis factor receptor superfamily, member 21 | 3.1 |
| Growth arrest and DNA-damage-inducible, alpha, b | 3.1 |
| CCAAT/enhancer binding protein (C/EBP), delta | 3.1 |
| Carboxypeptidase A4 | 3.0 |
| Elastase 3 like | 2.9 |
| Mitogen-activated protein kinase kinase kinase 1 | 2.9 |
| TBC1 domain family, member 12a | 2.8 |
| 2.6 | |
| 2.6 | |
| 2.5 | |
| Tryptophan 2,3-dioxygenase a | 21.8 |
| Interferon, gamma 1-2 | 6.2 |
| Fatty acid binding protein 1b, liver, tandem duplicate 2 | 4.8 |
| Cytochrome P450, family 3, subfamily A, polypeptide 65 | 4.5 |
| Geminin, DNA replication inhibitor | 4.4 |
| Microsomal triglyceride transfer protein | 4.3 |
| Inositol 1,4,5-trisphosphate receptor-interacting protein | 4.2 |
| Heparanase | 4.2 |
| Tumor protein p63 regulated 1-like | 4.2 |
| Receptor-type tyrosine-protein phosphatase S precursor | 3.7 |
| Major facilitator superfamily domain containing 2ab | 3.4 |
| RAS (RAD and GEM)-like GTP-binding 1 | 3.2 |
| Homogentisate 1,2-dioxygenase | 3.2 |
| ISG15 ubiquitin-like modifier | 3.1 |
| TSC22 domain family, member 3 | 3.0 |
| UDP glucuronosyltransferase 1 family polypeptide a1 | 3.0 |
| T-cell activation RhoGTPase activating protein b | 3.0 |
| VHSV-inducible protein— | 2.9 |
| UDP glucuronosyltransferase 1 family, polypeptide A7 | 2.9 |
| Interferon-induced very large GTPase 1-like | 2.8 |
| Mastermind-like transcriptional coactivator 3 | 2.7 |
| Forkhead box A2 | 2.7 |
| Complement component bfb | 2.7 |
| Cysteine-serine-rich nuclear protein 1a | 2.6 |
| Interferon regulatory factor 1b | 2.6 |
| Leucine-rich repeat and Ig domain containing 4a | 45.8 |
| Cyclin Y | 29.2 |
| Desumoylating isopeptidase 1a | 27.3 |
| GTPase IMAP family member 4 | 26.5 |
| Leucine-rich repeat, immunoglobulin-like and transmembrane domains 1b | 25.4 |
| Gap junction alpha-1 protein-like | 23.1 |
| Vomeronasal 2 receptor, c2 | 22.4 |
| Motilin receptor | 20.0 |
| Membrane-bound O-acyltransferase domain containing 4 | 19.8 |
| Neural cell adhesion molecule 2 | 17.7 |
| Hyperpolarization activated cyclic nucleotide-gated potassium channel 4 | 16.2 |
| Transmembrane protein 63B | 14.7 |
| 14.7 | |
| Semaphorin 7A, GPI membrane anchor | 14.6 |
| Transmembrane protein 237a | 14.3 |
| Protein phosphatase 1, regulatory subunit 3Aa | 14.2 |
| Toll-like receptor 1 | 14.1 |
| Ceramide synthase 2-like | 13.7 |
| Lysine (K)-specific methyltransferase 2E | 13.4 |
| Uridine-cytidine kinase 1 | 13.3 |
| Parathyroid hormone 1 receptor a | 13.2 |
| Zinc finger, MYND-type containing 12 | 13.2 |
| FEV (ETS oncogene family) | 12.9 |
| Pyruvate dehydrogenase kinase, isozyme 3a | 12.5 |
| finTRIM family, member 58 | 12.5 |
Gene ontology (GO) enrichment analysis of the top 25 most modulated genes in fish that previously received β-glucans and were then infected [Glucans-Spring Viremia Carp Virus (SVCV)] compared to untreated and infected fish (PBS-SVCV).
| GO name | GO category | |
|---|---|---|
| Medium-chain fatty acid transport | BP | 0.001 |
| Central nervous system myelin formation | 0.002 | |
| Tryptophan catabolic process to acetyl-CoA | 0.002 | |
| Tyrosine metabolic process | 0.002 | |
| Positive regulation of transcription of notch receptor target | 0.002 | |
| Lysophospholipid transport | 0.002 | |
| Long-chain fatty acid transport | 0.004 | |
| Transcytosis | 0.004 | |
| Tryptophan catabolic process to kynurenine | 0.004 | |
| 0.005 | ||
| Negative regulation of DNA replication | 0.005 | |
| Oligodendrocyte cell fate commitment | 0.005 | |
| Establishment of blood–brain barrier | 0.005 | |
| Axial mesoderm morphogenesis | 0.009 | |
| Homogentisate 1,2-dioxygenase activity | MF | 0.001 |
| Interferon-gamma receptor binding | 0.002 | |
| Tryptophan 2,3-dioxygenase activity | 0.002 | |
| Lipid transporter activity | 0.003 | |
| Detection of diacyl bacterial lipopeptide | BP | 0.001 |
| Positive regulation of interleukin-6 biosynthetic process | 0.001 | |
| Toll-like receptor 6 signaling pathway | 0.001 | |
| Peptidyl-serine octanoylation | 0.001 | |
| T-helper 1 type immune response | 0.001 | |
| Positive regulation of inositol phosphate biosynthetic process | 0.001 | |
| Regulation of cytokine secretion | 0.002 | |
| CTP salvage | 0.004 | |
| MyD88-dependent toll-like receptor signaling pathway | 0.005 | |
| UMP salvage | 0.006 | |
| Regulation of heart rate | 0.007 | |
| Pyrimidine nucleobase metabolic process | 0.009 | |
| Dorsal aorta development | 0.009 | |
| Parathyroid hormone receptor activity | MF | 0.002 |
| Peptide hormone binding | 0.003 | |
| Peptidyl-lysine acetyltransferase activity | 0.005 | |
| Uridine kinase activity | 0.005 | |
BP, biological process; MF, molecular function.
Figure 5Heatmaps representing different components related to lipid metabolism and transport. (A) Hormone genes involved in lipid metabolism. (B) Genes encoding key components of fatty acid oxidation. (C) Ketolysis. (D) Lipogenesis and cholesterol biosynthesis. A color gradient scheme representing gene modulation (red: lower expression; green: higher expression) is shown on the bottom.
Figure 6Effect of Ifng1-2 on the activation of immune cells and on survival against Spring Viremia Carp Virus (SVCV). (A) Zebrafish larvae overexpressing ifng1-2 show the activation of macrophages and neutrophils, with an evident change in morphology from a spherical morphology to a dendritic morphology. (B) Kaplan–Meier survival curves after SVCV challenge in zebrafish larvae overexpressing or not overexpressing ifng1-2 (C) Kaplan–Meier survival curves after SVCV challenge in adult zebrafish co-inoculated or not co-inoculated with the Ifng1-2 recombinant protein. Significant differences are represented by asterisks (*p < 0.05).
Figure 7Analysis of the kynurenine pathway of tryptophan catabolism in zebrafish inoculated with β-glucans. (A) Schematic representation of the kynurenine pathway and the DEGs in the comparison Glucans-Spring Viremia Carp Virus (SVCV) vs. Glucans-PBS (tdo2a, kyat2) and the comparison Glucans-SVCV vs. PBS (tph2). (B) Heatmap representing some of the most affected genes after β-glucan treatment. Whereas ifng1-2 and tdo2a are highly expressed in the Glucans-SVCV group, tph2 and kyat2 have lower expression levels in these fish. A color gradient scheme representing gene modulation (red: lower expression; green: higher expression) is shown on the bottom. (C) Kaplan–Meier survival curves representing the effect of a TDO-inhibitor (C80C91) and an IDO-inhibitor (1-MT) during a challenge with SVCV in adult zebrafish. A significant increase in the survival rate was observed in individuals inoculated with the inhibitors. Significant differences are represented by asterisks (*p < 0.05).